EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cutaneous Adverse-Event Reporting Patterns of Bruton Tyrosine Kinase Inhibitors: A Multi-Database Pharmacovigilance Analysis

Saikat Mandal, Manideepa Maji, Ashish Sharma, Arkadeep Dhali

Cancers · 16.11.2026 · 18 (22) · 3660

DOI: 10.3390/cancers18223660 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 16.11.2026. Verfasst von Saikat Mandal und 3 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIHR Nottingham Biomedical Research Centre, UK Research and Innovation, NIHR Academic Clinical Fellowship.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bruton tyrosine kinase inhibitors (BTKi) are widely used for B-cell malignancies and chronic graft-versus-host disease, but their real-world dermatologic reporting profile remains incompletely defined.

Methods

We performed a multi-database pharmacovigilance analysis of BTKi primary suspect reports in FAERS, Canada Vigilance, and JADER. Outcomes included any-cutaneous adverse event, a prespecified 14-category morphology panel, severe cutaneous reaction controls, cutaneous malignancy, latency, and exploratory wound/ulcer and neutrophilic-dermatosis phenotypes. Reporting odds ratios (RORs), Evans criteria, a mutually exclusive haematologic-oncology disease-context comparator, multivariable models, and cross-database replication were used.

Results

FAERS contained 75,681 BTKi primary suspect reports among 12,838,382 reports; Canada Vigilance contained 4649 among 1,234,555; and JADER contained 1822 BTKi suspect reports among 1,027,194. Vascular-cutaneous events showed the most prominent class-level reporting pattern (FAERS ROR 7.97, 95% CI 7.43–8.56; disease-context ROR 6.38, 95% CI 5.84–6.97), with similar disproportionate reporting observed in Canada Vigilance and JADER. Of 802 vascular-cutaneous reports, 777 (96.9%) described bleeding manifestations without vasculitis, whereas 22 (2.7%) included vasculitis as a reported event; cutaneous vasculitis itself was not disproportionately reported (19 reports; ROR 1.38, 95% CI 0.89–2.16). Wound/ulcer events met the Evans criteria for disproportionate reporting in FAERS and were directionally elevated against the full Canada Vigilance background, but not against the Canadian disease-context comparator. Exploratory analyses showed disproportionate reporting for the neutrophilic-core phenotype (disease-context ROR 1.99, 95% CI 1.50–2.66) and pyoderma gangrenosum (ROR 2.87, 95% CI 1.98–4.16). Non-melanoma skin cancer remained disproportionately reported after disease-context adjustment in FAERS (adjusted OR 1.54, 95% CI 1.39–1.71), and was reproduced in Canada Vigilance. A shorter latency period was identified for bleeding than for cutaneous malignancy (median, 1.1 vs. 9.3 months). In SJS/TEN culprit-drug co-exposure analyses, concomitant BTK inhibitor exposure did not show greater disproportionate SJS/TEN reporting than the corresponding culprit-drug-only groups.

Conclusions

BTKi-associated dermatologic reports identified three main patterns: early cutaneous bleeding, wound-and-ulcer events with an exploratory neutrophilic-dermatosis component, and later cutaneous malignancy. These findings support the early assessment of bleeding and non-healing ulcers and longer-term skin surveillance during BTKi treatment. Spontaneous-reporting data cannot determine incidence, confirm causality, establish comparative product safety, or accurately adjudicate clinical diagnoses and event timing.

Förderung

  • NIHR Nottingham Biomedical Research Centre
  • UK Research and Innovation
  • NIHR Academic Clinical Fellowship

Zitieren

APA

Mandal, S., Maji, M., Sharma, A., & Dhali, A. (2026). Cutaneous Adverse-Event Reporting Patterns of Bruton Tyrosine Kinase Inhibitors: A Multi-Database Pharmacovigilance Analysis. Cancers, 18(22), 3660. https://doi.org/10.3390/cancers18223660

Vancouver

Mandal S, Maji M, Sharma A, Dhali A. Cutaneous Adverse-Event Reporting Patterns of Bruton Tyrosine Kinase Inhibitors: A Multi-Database Pharmacovigilance Analysis. Cancers. 2026;18(22):3660. doi:10.3390/cancers18223660

BibTeX
@article{Mandal2026,
  author = {Mandal, Saikat and Maji, Manideepa and Sharma, Ashish and Dhali, Arkadeep},
  title = {Cutaneous Adverse-Event Reporting Patterns of Bruton Tyrosine Kinase Inhibitors: A Multi-Database Pharmacovigilance Analysis},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {22},
  pages = {3660},
  doi = {10.3390/cancers18223660}
}
Kostenlos starten →